Diary - News
All news Osivax announces the closing of a EUR2.7M seed funding round
Lyon, France – June 15th, 2017 – Osivax, a clinical-stage biotech start’up focused on vaccines and based in Lyon (France), announces today the closing of a seed funding round of EUR 2.7 million. Osivax was recently created as a spin-off of the R&D department of Imaxio, a biotech company also based in Lyon. The objectives of the spin-off are to enable Osivax to focus on the development of the R&D platform and Imaxio to accelerate the commercial development of its leptospirosis vaccine commercialized currently in France and soon internationally.
Read the press release
